18 March 2010

ImmuPharma ponders funding

01/07/2008 Robert Tyerman

Drug discoverer ImmuPharma is understood to be contemplating raising between £1.5 million and £5 million at around 60p to fund developments with a range of products. These include Lupuzor, its key IPP-201101 treatment candidate for Lupus Erythematosus, a chronic auto-immune disease that damages skin, joints, blood vessels, various organs and the nervous system.

The AIM-quoted company awaits the results of a 200-patient Phase IIb efficacy study for Lupuzor, due this autumn. Recently, ImmuPharma announced that pre-clinical trial data showed that another of its products, IPP-204106, could curb the growth of many human cancer cell lines, with ‘in vivo’ studies showing most tumours completely eradicated and survival time increased without additional treatment.

Richard Warr, chairman of London-based ImmuPharma, commented on IPP-204106, ‘This exciting new drug has tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic.’ But most analysts see Lupuzor as the company’s biggest potential winner.

ImmuPharma is in collaboration with CNRS, the national scientific research centre of France, which is providing it with access both to leading scientists and possible grant opportunities. Being a development company, ImmuPharma lost £3.3 million last year, which it closed with cash of £2.9 million.

Shares in ImmuPharma have fluctuated between 40.5p and 84.5p over the past three years and now stand at 65.75p, valuing the company at £48 million. They offer significant speculative potential over the medium term.

Companies: ImmuPharma

Subscribe today

£7,277

That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.

Subscribe now and receive a 50% discount

AIM in Review 2010

Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Directors' Pay on AIM 2009 – ­ a Growth Company Investor publication in association with Deloitte

The report reveals the top-earning chief executives and remuneration levels at AIM's most profitable and fastest-growing companies. It also examines constituent parts, including basic salary, bonus, pensions, benefits and share-based payments. To order click here.

Free – Latest Stock Recommendations

Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.

Select your level of risk and we select the funds

Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.

The AIM Guide 2009/10

The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies.   Order your copy today and benefit from a £10 discount!

VCT Special Report 2009

This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.

Cash Shells Special Report 2009

Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Turnaround at TEG 17/03/2010

Organic composting specialist TEG Group is pursuing long-term contracts after turning £1.6 million annual losses into £155,000 pre-tax profits.

Tags: AIM , Growth Stocks , Mergers & acquisitions , Turnaround

Sector: General Industrials

Companies: TEG (formerly TEG Environmental)

Cyprotex broadens its scope 17/03/2010

Bid candidate Cyprotex is moving its drug discovery services into toxicology after pre-tax profits down 15 per cent to £460,413.

Tags: AIM , Cash , Mergers & acquisitions

Sector: Pharmaceuticals & Biotechnology

Companies: Cyprotex

West African hopes cheer Forte 16/03/2010

Forte Energy expects new uranium resource figures for its Mauritanian projects shortly and could start producing from Guinea by 2012.

Tags: AIM , Commodities , Deals & contracts

Sector: Mining

Companies: Forte Energy

More News

Sectors

Vitesse Media Events